Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2014 09/11/2014 09/12/2014 09/15/2014 09/16/2014 Date
69.48(c) 68.8(c) 68(c) 66.79(c) 66.62 Last
955 382 1 140 007 686 874 1 016 598 336 588 Volume
+1.83% -0.98% -1.16% -1.78% -0.25% Change
More quotes
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company operates its business through one segment, the biopharmaceutical development and commercialization segment. Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
09/16Presentation
Surperformance© rating of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More about the company
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 752 M
EBIT 2014 -146 M
Net income 2014 -188 M
Debt 2014 249 M
Yield 2014 -
Sales 2015 858 M
EBIT 2015 -144 M
Net income 2015 -169 M
Debt 2015 323 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 13,6x
EV / Sales 2015 12,0x
Capitalization 10 004 M
More Financials
Latest news on BIOMARIN PHARMACEUTICAL IN
1d ago BIOMARIN PHARMACEUTICAL : Named by CenterWatch as One of the Fastest Developers ..
6d ago BIOMARIN PHARMACEUTICAL : Technical Coverage of Biotech Stocks - Dyax, Alexion P..
6d ago BIOMARIN PHARMACEUTICAL : to Attend Upcoming Investor Conferences in London
08/26 BIOMARIN PHARMACEUTICAL : Assigned Patent
08/25 Roche to buy U.S. biotech firm InterMune for $8.3 billion
08/19 BIOMARIN PHARMACEUTICAL : to Present at Upcoming Investor Conferences
08/13 BIOMARIN PHARMACEUTICAL : Investigators at BioMarin Pharmaceutical Discuss Findi..
08/01 BIOMARIN PHARMACEUTICAL : Entry into a Material Definitive Agreement (form 8-K)
07/30 BIOMARIN PHARMACEUTICAL : Patent Issued for Formulations for Lysosomal Enzymes
07/30DJBioMarin Sells Priority Review Voucher To Regeneron
07/30 BIOMARIN PHARMACEUTICAL : Results of Operations and Financial Condition, Financi..
07/30 BioMarin Announces Second Quarter 2014 Financial Results
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
BioMarin Pharmaceutical In : Income Statement Evolution
More Financials
EPS Revisions
BioMarin Pharmaceutical In : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF